TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TREACE MEDICAL CONCEPTS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.88+0.01 (+0.26%)
Close on Oct 19, 2026
- Market cap
- $252.39M
- P/E (TTM)
- –
- Dividend yield
- –
Treace Medical Concepts statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Market Cap | $252.33M | $230.55M |
| Enterprise Value | $265.93M | $202.97M |
| PS Ratio | 1.23 | 3.10 |
| PB Ratio | 3.73 | 3.04 |
| P/TBV Ratio | 5.23 | 4.43 |
Enterprise value
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| EV / Sales | 1.30 | 2.91 |
Income (trailing twelve months)
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Revenue | $205.31M | $102.39M |
| Gross Profit | $163.12M | $60.36M |
| Operating Income | -$53.72M | -$4.31M |
| Net Income | -$59.52M | -$6.57M |
| EBITDA | -$45.35M | -$1.98M |
| EPS (Diluted) | -$0.93 | -$0.08 |
Margins
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Gross Margin | 79.5% | 55.2% |
| Operating Margin | -26.2% | -6.04% |
| Profit Margin | -29.0% | -10.5% |
| EBITDA Margin | -22.1% | -2.67% |
| FCF Margin | -12.2% | 0.02% |
Returns
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Return on Equity (ROE) | -72.0% | -18.2% |
| Return on Assets (ROA) | -30.7% | -13.3% |
| Return on Invested Capital (ROIC) | -51.7% | -3.69% |
| Return on Capital Employed (ROCE) | -38.5% | -9.07% |
Growth
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -3.95% | 8.85% |
| Revenue Growth (3Y CAGR) | 14.5% | 7.08% |
| Revenue Growth (5Y CAGR) | 30.0% | 11.8% |
Balance sheet
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $45.62M | $36.66M |
| Total Debt | $59.21M | $97.65M |
| Net Cash (Debt) | -$13.59M | $3.92M |
| Net Cash Per Share | -$0.21 | $0.28 |
| Equity (Book Value) | $67.74M | $55.33M |
| Book Value Per Share | $1.04 | $2.87 |
| Tangible Book Value | $48.27M | $10.79M |
| Working Capital | $78.96M | $56.72M |
Financial position
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Current Ratio | 2.90 | 2.48 |
| Quick Ratio | 1.79 | 1.53 |
| Debt / Equity | 0.87 | 0.41 |
| Interest Coverage | -9.23 | -1.85 |
Cash flow (trailing twelve months)
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Operating Cash Flow | -$14.58M | -$566.22K |
| Capital Expenditures | -$10.47M | -$3.69M |
| Free Cash Flow | -$25.05M | -$696.00K |
| FCF Per Share | -$0.39 | -$0.02 |
Efficiency
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Asset Turnover | 1.06 | 0.58 |
| Inventory Turnover | 1.03 | 2.21 |
| Revenue Per Employee | $456.24K | $322.92K |
| Profits Per Employee | -$132.26K | -$51.88K |
| Employee Count | 450 | 185 |
Dividends and yields
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Earnings Yield | -23.6% | -6.88% |
| FCF Yield | -9.93% | -0.45% |
Shares
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Shares Outstanding | 65,034,600 | 44,302,700 |
| Shares Change (YoY) | 2.71% | 3.36% |
| Float | 46,772,900 | 37,462,700 |
| Shares Held by Insiders | 28.1% | 10.5% |
| Shares Held by Institutions | 49.0% | 63.5% |
Scores
| Measure | Treace Medical Concepts | Industry median |
|---|---|---|
| Altman Z-Score | -0.17 | 1.95 |
| Piotroski F-Score | 2 | 5 |
| Beneish M-Score | -3.50 | -2.64 |
Calculated by StockData from Treace Medical Concepts's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.